Literature DB >> 21455212

Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.

B C Kraljacic, M Arguello, A Amri, G Cormack, K Borden.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21455212     DOI: 10.1038/leu.2011.57

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  23 in total

Review 1.  Targeting Translation of mRNA as a Therapeutic Strategy in Cancer.

Authors:  Ipsita Pal; Maryam Safari; Marko Jovanovic; Susan E Bates; Changchun Deng
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

2.  Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.

Authors:  J Cao; X Sun; X Zhang; D Chen
Journal:  Clin Transl Oncol       Date:  2017-10-30       Impact factor: 3.405

3.  eIF4E3 acts as a tumor suppressor by utilizing an atypical mode of methyl-7-guanosine cap recognition.

Authors:  Michael J Osborne; Laurent Volpon; Jack A Kornblatt; Biljana Culjkovic-Kraljacic; Aurélie Baguet; Katherine L B Borden
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

4.  A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.

Authors:  Sarit Assouline; Biljana Culjkovic-Kraljacic; Julie Bergeron; Stephen Caplan; Eftihia Cocolakis; Caroline Lambert; Cara J Lau; Hiba Ahmad Zahreddine; Wilson H Miller; Katherine L B Borden
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

Review 5.  The oncologic burden of hepatitis C virus infection: A clinical perspective.

Authors:  Harrys A Torres; Terri Lynn Shigle; Nassim Hammoudi; James T Link; Felipe Samaniego; Ahmed Kaseb; Vincent Mallet
Journal:  CA Cancer J Clin       Date:  2017-07-06       Impact factor: 508.702

Review 6.  The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.

Authors:  Michael J Osborne; Katherine L B Borden
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

Review 7.  Aiding and abetting cancer: mRNA export and the nuclear pore.

Authors:  Biljana Culjkovic-Kraljacic; Katherine L B Borden
Journal:  Trends Cell Biol       Date:  2013-04-10       Impact factor: 20.808

Review 8.  The oncogene eIF4E: using biochemical insights to target cancer.

Authors:  Martin Carroll; Katherine L B Borden
Journal:  J Interferon Cytokine Res       Date:  2013-03-08       Impact factor: 2.607

9.  Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.

Authors:  Rui Wang; Lijuan Xia; Janice Gabrilove; Samuel Waxman; Yongkui Jing
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

10.  The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia.

Authors:  F Hariri; M Arguello; L Volpon; B Culjkovic-Kraljacic; T H Nielsen; J Hiscott; K K Mann; K L B Borden
Journal:  Leukemia       Date:  2013-03-07       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.